Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2017

Open Access 01-12-2017 | Review

A systematic literature review of health state utility values in head and neck cancer

Authors: Michela Meregaglia, John Cairns

Published in: Health and Quality of Life Outcomes | Issue 1/2017

Login to get access

Abstract

Background

Health state utility values (HSUVs) are essential parameters in model-based economic evaluations. This study systematically identifies HSUVs in head and neck cancer and provides guidance for selecting them from a growing body of health-related quality of life studies.

Methods

We systematically reviewed the published literature by searching PubMed, EMBASE and The Cochrane Library using a pre-defined combination of keywords. The Tufts Cost-Effectiveness Analysis Registry and the School of Health and Related Research Health Utilities Database (ScHARRHUD) specifically containing health utilities were also queried, in addition to the Health Economics Research Centre database of mapping studies. Studies were considered for inclusion if reporting original HSUVs assessed using established techniques. The characteristics of each study including country, design, sample size, cancer subsite addressed and demographics of responders were summarized narratively using a data extraction form. Quality scoring and critical appraisal of the included studies were performed based on published recommendations.

Results

Of a total 1048 records identified by the search, 28 studies qualified for data extraction and 346 unique HSUVs were retrieved from them. HSUVs were estimated using direct methods (e.g. standard gamble; n = 10 studies), multi-attribute utility instruments (MAUIs; n = 13) and mapping techniques (n = 3); two studies adopted both direct and indirect approaches. Within the MAUIs, the EuroQol 5-dimension questionnaire (EQ-5D) was the most frequently used (n = 11), followed by the Health Utility Index Mark 3 (HUI3; n = 2), the 15D (n = 2) and the Short Form-Six Dimension (SF-6D; n = 1). Different methods and types of responders (i.e. patients, healthy subjects, clinical experts) influenced the magnitude of HSUVs for comparable health states. Only one mapping study developed an original algorithm using head and neck cancer data. The identified studies were considered of intermediate quality.

Discussion

This review provides a dataset of HSUVs systematically retrieved from published studies in head and neck cancer. There is currently a lack of research for some disease phases including recurrent and metastatic cancer, and treatment-related complications. In selecting HSUVs for cost-effectiveness modeling purposes, preference should be given to EQ-5D utility values; however, mapping to EQ-5D is a potentially valuable technique that should be further developed in this cancer population.
Appendix
Available only for authorised users
Literature
1.
Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in health care. Annu Rev Public Health. 2000;21:587–611.CrossRefPubMed
2.
3.
Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016;19(6):704–19.CrossRefPubMed
4.
Rashidi AA, Anis AH, Marra CA. Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with health utilities index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. Health Qual Life Outcomes. 2006;4:25.CrossRefPubMedPubMedCentral
5.
Witney AG, Treharne GJ, Tavakoli M, Lyons AC, Vincent K, Scott DL, et al. The relationship of medical, demographic and psychosocial factors to direct and indirect health utility instruments in rheumatoid arthritis. Rheumatology. 2006;45(8):975–81.CrossRefPubMed
6.
Dolan P, Sutton M. Mapping visual analogue scale health state valuations onto standard gamble and time trade-off values. Soc Sci Med. 1997;44(10):1519–30.CrossRefPubMed
7.
Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5–21.CrossRefPubMed
8.
9.
Wiedermann W, Frick U. Using surveys to calculate disability-adjusted life-year. Alcohol Res. 2013;35(2):128–33.PubMed
10.
Attema AE, Edelaar-Peeters Y, Versteegh MM, Stolk EA. Time trade-off: one methodology, different methods. Eur J Health Econ. 2013 Jul;14(Suppl 1):S53–64.CrossRefPubMed
11.
Richardson J, Khan MA, Iezzi A, Maxwell A. Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF-6D, HUI3, 15D, QWB, and AQoL-8D multi-attribute utility instruments. Med Decis Mak. 2015;35:276–91.CrossRef
12.
Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes. Value Health. 2014;17(4):462–70.CrossRefPubMed
13.
EUnetHTA. Methods for health economic evaluations – a guideline based on current practices in Europe. Copyright © EUnetHTA 2014.
14.
Hao Y, Wolfram V, Cook J. A structured review of health utility measures and elicitation in advanced/metastatic breast cancer. Clinicoecon Outcomes Res. 2016;8:293–303.PubMedPubMedCentral
15.
Boye KS, Matza LS, Feeny DH, Johnston JA, Bowman L, Jordan JB. Challenges to time trade-off utility assessment methods: when should you consider alternative approaches? Expert Rev Pharmacoecon Outcomes Res. 2014;14(3):437–50.CrossRefPubMed
16.
Horsman J, Furlong W, Feeny D, Torrance G. The health utilities index (HUI®): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.CrossRefPubMedPubMedCentral
17.
18.
Hawthorne G, Richardson J, Osborne R. The assessment of quality of life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res. 1999;8(3):209–24.CrossRefPubMed
19.
Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Health. 2017;20(1):18–27.CrossRefPubMed
20.
Szabo SM, Dobson RL, Donato BMK, L’Italien G, Hotte SJ, Levy AR. The quality-of-life impact of head and neck cancer: preference values from the Canadian general public. Health Outcomes Res Med. 2012;3(1):e11–23.CrossRef
21.
22.
Liberato NL, Rognoni C, Rubrichi S, Quaglini S, Marchetti M, Gorlia T, et al. Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis. Ann Oncol. 2012;23(7):1825–32.CrossRefPubMed
23.
Komatsuzaki Y, Gramegna P, Stephens JM, Botteman MF, Pashos CL, Redaelli A. Preferences and utilities of health outcomes and treatments associated with head and neck cancer: a systematic review. Am J Cancer. 2006;5(1):27–34.CrossRef
24.
25.
26.
Papaioannou D, Brazier J, Paisley S. Systematic searching and selection of health state utility values from the literature. Value Health. 2013;16:686–95.CrossRefPubMed
27.
28.
Gheorghe A, Moran G, Duffy H, Roberts T, Pinkney T, Calvert M. Health utility values associated with surgical site infection: a systematic review. Value Health. 2015;18(8):1126–37.CrossRefPubMed
29.
30.
31.
32.
Smith-Palmer J, Bae JP, Boye KS, Norrbacka K, Hunt B, Valentine WJ. Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes. Clinicoecon Outcomes Res. 2016;8:559–71.CrossRefPubMedPubMedCentral
33.
Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Mak. 2001;21(4):329–34.CrossRef
34.
35.
Linendoll N, Saunders T, Burns R, Nyce JD, Wendell KB, Evens AM, et al. Health-related quality of life in Hodgkin lymphoma: a systematic review. Health Qual Life Outcomes. 2016;14(1):114.CrossRefPubMedPubMedCentral
36.
Marcellusi A, Capone A, Favato G, Mennini FS, Baio G, Haeussler K, HPV Italian Collaborative Study Group, et al. Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group. Clin Ther. 2015;37(1):156–167.e4.CrossRefPubMed
37.
Noel CW, Lee DJ, Kong Q, Xu W, Simpson C, Brown D, et al. Comparison of health state utility measures in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2015;141(8):696–703.CrossRefPubMed
38.
Conway EL, Farmer KC, Lynch WJ, Rees GL, Wain G, Adams J. Quality of life valuations of HPV-associated cancer health states by the general population. Sex Transm Infect. 2012;88(7):517–21.CrossRefPubMedPubMedCentral
39.
Hamilton DW, Bins JE, McMeekin P, Pedersen A, Steen N, De Soyza A, et al. Quality compared to quantity of life in laryngeal cancer: a time trade-off study. Head Neck. 2016;38(Suppl 1):E631–7.CrossRefPubMed
40.
Hollenbeak CS, Lowe VJ, Stack BC Jr. The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck. Cancer. 2001;92(9):2341–8.CrossRefPubMed
41.
Jalukar V, Funk GF, Christensen AJ, Karnell LH, Moran PJ. Health states following head and neck cancer treatment: patient, health-care professional, and public perspectives. Head Neck. 1998;20(7):600–8.CrossRefPubMed
42.
Ringash J, Redelmeier DA, O'Sullivan B, Bezjak A. Quality of life and utility in irradiated laryngeal cancer patients. Int J Radiat Oncol Biol Phys. 2000;47(4):875–81.CrossRefPubMed
43.
Weiss MH, Harrison LB, Isaacs RS. Use of decision analysis in planning a management strategy for the stage N0 neck. Arch Otolaryngol Head Neck Surg. 1994;120(7):699–702.CrossRefPubMed
44.
de Almeida JR, Villanueva NL, Moskowitz AJ, Miles BA, Teng MS, Sikora A, et al. Preferences and utilities for health states after treatment for oropharyngeal cancer: transoral robotic surgery versus definitive (chemo)radiotherapy. Head Neck. 2014;36(7):923–33.CrossRefPubMed
45.
Llewellyn-Thomas HA, Sutherland HJ, Thiel EC. Do patients' evaluations of a future health state change when they actually enter that state? Med Care. 1993;31(11):1002–12.CrossRefPubMed
46.
van der Donk J, Levendag PC, Kuijpers AJ, Roest FH, Habbema JD, Meeuwis CA, et al. Patient participation in clinical decision-making for treatment of T3 laryngeal cancer: a comparison of state and process utilities. J Clin Oncol. 1995;13(9):2369–78.CrossRefPubMed
47.
del Barco ME, Mesía R, Adansa Klain JC, Vázquez Fernández S, Martínez-Galán J, Pastor Borgoñon M. Et al; Spanish head and neck cancer cooperative group (TTCC). Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study. Oral Oncol. 2016;62:54–9.CrossRef
48.
Ouattassi N, Benmansour N, El Fakir S, Nejjari C, Alami MN. Translation and validation of EORTC QLQ-H&N 35 into Moroccan Arabic for ENT head and neck cancer patients in Morocco. Eur Arch Otorhinolaryngol. 2016;273(9):2727–34.CrossRefPubMed
49.
Parrilla C, Minni A, Bogaardt H, Macri GF, Battista M, Roukos R, et al. Pulmonary rehabilitation after Total Laryngectomy: a multicenter time-series clinical trial evaluating the Provox XtraHME in HME-Naïve patients. Ann Otol Rhinol Laryngol. 2015;124(9):706–13.CrossRefPubMed
50.
Rogers SN, Miller RD, Ali K, Minhas AB, Williams HF, Lowe D. Patients' perceived health status following primary surgery for oral and oropharyngeal cancer. Int J Oral Maxillofac Surg. 2006;35(10):913–9.CrossRefPubMed
51.
Ramaekers BL, Joore MA, Grutters JP, van den Ende P. Jong Jd, Houben R, et al. the impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. Oral Oncol. 2011;47(8):768–74.CrossRefPubMed
52.
Pickard AS, Jiang R, Lin HW, Rosenbloom S, Cella D. Using patient-reported outcomes to compare relative burden of cancer: EQ-5D and functional assessment of cancer therapy-general in eleven types of cancer. Clin Ther. 2016;38(4):769–77.CrossRefPubMed
53.
Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, et al. Quality of life and performance status from a sub-study conducted within a prospective phase 3 randomized trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for locally advanced head and neck carcinoma: NRG oncology radiation therapy oncology group 0522. Int J Radiat Oncol Biol Phys. 2017;97(4):687–99.CrossRefPubMed
54.
Govers TM, Schreuder WH, Klop WM, Grutters JP, Rovers MM, Merkx MA, et al. Quality of life after different procedures for regional control in oral cancer patients: cross-sectional survey. Clin Otolaryngol. 2016;41(3):228–33.CrossRefPubMed
55.
Pottel L, Lycke M, Boterberg T, Pottel H, Goethals L, Duprez F, et al. G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radio-chemotherapy. BMC Cancer. 2015;15:875.CrossRefPubMedPubMedCentral
56.
Aro K, Bäck L, Loimu V, Saarilahti K, Rogers S, Sintonen H, et al. Trends in the 15D health-related quality of life over the first year following diagnosis of head and neck cancer. Eur Arch Otorhinolaryngol. 2016;273(8):2141–50.CrossRefPubMed
57.
Loimu V, Mäkitie AA, Bäck LJ, Sintonen H, Räsänen P, Roine R, et al. Health-related quality of life of head and neck cancer patients with successful oncological treatment. Eur Arch Otorhinolaryngol. 2015;272(9):2415–23.CrossRefPubMed
58.
Higgins KM. What treatment for early-stage glottic carcinoma among adult patients: CO2 endolaryngeal laser excision versus standard fractionated external beam radiation is superior in terms of cost utility? Laryngoscope. 2011;121(1):116–34.CrossRefPubMed
59.
Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW, Hays RD. Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer. 2015;121(5):758–65.CrossRefPubMed
60.
Chan KK, Willan AR, Gupta M, Pullenayegum E. Underestimation of uncertainties in health utilities derived from mapping algorithms involving health-related quality-of-life measures: statistical explanations and potential remedies. Med Decis Mak. 2014;34(7):863–72.CrossRef
61.
Parthan A, Posner MR, Brammer C, Beltran P, Jansen JP. Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck. 2009;31(10):1255–62.CrossRefPubMed
62.
Yong JH, Beca J, O'Sullivan B, Huang SH, McGowan T, Warde P, et al. Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer. Clin Oncol (R Coll Radiol). 2012;24(7):532–8.CrossRef
63.
Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res. 2004;13(7):1247–53.CrossRefPubMed
64.
Nichol MB, Sengupta N, Globe DR. Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med Decis Mak. 2001;21(2):105–12.CrossRef
65.
Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66(4):981–91.CrossRefPubMed
66.
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M; EORTC 24971/TAX 323 Study Group, .et al, Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695-1704.CrossRefPubMed
67.
Heiskanen J, Tolppanen AM, Roine RP, Hartikainen J, Hippeläinen M, Miettinen H, et al. Comparison of EQ-5D and 15D instruments for assessing the health-related quality of life in cardiac surgery patients. Eur Heart J Qual Care Clin Outcomes. 2016;2(3):193–200.CrossRef
68.
Vainiola T, Pettilä V, Roine RP, Räsänen P, Rissanen AM, Sintonen H. Comparison of two utility instruments, the EQ-5D and the 15D, in the critical care setting. Intensive Care Med. 2010;36(12):2090–3.CrossRefPubMedPubMedCentral
69.
Lunde L. Can EQ-5D and 15D be used interchangeably in economic evaluations? Assessing quality of life in post-stroke patients. Eur J Health Econ. 2013;14:539–50.CrossRefPubMed
70.
Vartiainen P, Mäntyselkä P, Heiskanen T, Hagelberg N, Mustola S, Forssell H, et al. Validation of EQ-5D and 15D in the assessment of health-related quality of life in chronic pain. Pain. 2017;158(8):1577–85.CrossRefPubMed
71.
Arnold D, Girling A, Stevens A, Lilford R. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis. BMJ. 2009;339:b2688.CrossRefPubMedPubMedCentral
72.
Dennett SL, Boye KS, Yurgin NR. The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health. 2008;11(3):478–86.CrossRefPubMed
73.
McDonough CM, Tosteson AN. Measuring preferences for cost-utility analysis: how choice of method may influence decision-making. Pharmaco Economics. 2007;25(2):93–106.CrossRef
74.
Brazier J, Rowen D. NICE DSU Technical Support Document 11: Alternatives to EQ-5D for Generating Health State Utility Values [Internet]. In: NICE Decision Support Unit Technical Support Documents. London: National Institute for Health and Care Excellence (NICE); 2011.
75.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16:231–50.CrossRefPubMed
76.
Meregaglia M, Cairns J. Economic evaluations of follow-up strategies for cancer survivors: a systematic review and quality appraisal of the literature. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):913–29.CrossRefPubMed
77.
78.
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group: The EORTC QLQ-C30 scoring manual, 3rd edition. European Organization for Research and Treatment of Cancer (EORTC), Brussels (2001).
79.
Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995;75(5):1151–61.CrossRefPubMed
Metadata
Title
A systematic literature review of health state utility values in head and neck cancer
Authors
Michela Meregaglia
John Cairns
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2017
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-017-0748-z

Other articles of this Issue 1/2017

Health and Quality of Life Outcomes 1/2017 Go to the issue

Research

Profile and predictors of health related quality of life among type II diabetes mellitus patients in Quetta city, Pakistan

Research

Health-related quality of life in pregnant women living with HIV: a comparison of EQ-5D and SF-12

Research

Assessment of the consequences of caregiving in psychosis: a psychometric comparison of the Zarit Burden Interview (ZBI) and the Involvement Evaluation Questionnaire (IEQ)

Review

Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma

Research

Impact of smoking on health-related quality of Life after percutaneous coronary intervention treated with drug-eluting stents: a longitudinal observational study

Research

Development of a Microsoft Excel tool for applying a factor retention criterion of a dimension coefficient to a survey on patient safety culture